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PHASE I STUDIES
Phase 1b trial of proteasome inhibitor carfilzomib
with irinotecan in lung cancer and other irinotecan-sensitive
malignancies that have progressed on prior therapy
(Onyx IST reference number: CAR-IST-553)
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Summary Introduction Proteasome inhibition is an established
therapy formanymalignancies. Carfilzomib, a novel proteasome
inhibitor, was combined with irinotecan to provide a syner-
gistic approach in relapsed, irinotecan-sensitive cancers.
Materials and Methods Patients with relapsed irinotecan-
sensitive cancers received carfilzomib (Day 1, 2, 8, 9, 15,
and 16) at three dose levels (20/27 mg/m2, 20/36 mg/m2
and 20/45 mg/m2/day) in combination with irinotecan (Days
1, 8 and 15) at 125mg/m2/day. Key eligibility criteria included
measurable disease, a Zubrod PS of 0 or 1, and acceptable
organ function. Patients with stable asymptomatic brain
metastases were eligible. Dose escalation utilized a stan-
dard 3 + 3 design. Results Overall, 16 patients were
enrolled to three dose levels, with four patients replaced.
Three patients experienced dose limiting toxicity (DLT) and
the maximum tolerated dose (MTD) was exceeded in Cohort
3. The RP2 dose was carfilzomib 20/36 mg/m2 (given on
Days 1, 2, 8, 9, 15, and 16) and irinotecan 125 mg/m2
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(Days 1, 8 and 15). Common Grade (Gr) 3 and 4 toxicities
included fatigue (19%), thrombocytopenia (19%), and diarrhea
(13%). Conclusions Irinotecan and carfilzomib were well
tolerated, with common toxicities of fatigue, thrombocyto-
penia and neutropenic fever. Objective clinical response
was 19% (one confirmed partial response (PR) in small
cell lung cancer (SCLC) and two unconfirmed); stable dis-
ease (SD) was 6% for a disease control rate (DCR) of
25%. The recommended phase II dose was carfilzomib
20/36 mg/m2 and irinotecan125 mg/m2. The phase II evalua-
tion is ongoing in relapsed small cell lung cancer.
Keywords Lung cancer . Carfilzomib . Phase I . Irinotecan
Abbreviations
AE Adverse Event
ALT Alanine Transaminase
AST Aspartate Aminotransferase
BSA Body Surface Area
CLA Chymotrypsin-Like Activity
CTCAE Common Terminology Criteria For Adverse
Events
BSA Body Surface Area
DCR Disease Control Rate
DLT Dose Limiting Toxicity
FDA Food And Drug Adminstration
Gr Grade
HIV Human Immunodeficiency Virus
IRB Institutional Review Board
i.v. Intravenous
MTD Maximum Tolerated Dose
NYHA New York Heart Association
NSCLC Non-Small Cell Lung Cancer
NF-κB Nuclear Factor-κB
PR Partial Responses
PBMC Peripheral Blood Mononuclear Cell
PFS Progression-Free Survival
RECIST Response Evaluation Criteria In Solid Tumors
RR Response Rate
SCLC Small Cell Lung Cancer
TLS Tumor Lysis Syndrome
Introduction
Small cell lung cancer (SCLC) is well recognized for its initial
sensitivity to chemotherapy, but ultimate recurrence and resis-
tance to subsequent lines of therapy. The overall prognosis
remains poor, with a two-year overall survival of less than
5% and a median survival of approximately nine to 11 months
[1], attributable to the lack of effective salvage regimens for
this disease. Currently, Food and Drug Adminstration (FDA)-
approved second-line therapies provide minimal extension of
life. We developed a novel combination therapy using
irinotecan and a proteasome inhibitor, carfilzomib, and report
the initial safety profile of this combination.
The proteasome is a multicatalytic proteinase complex that
first ubiquinates and then degrades a variety of protein sub-
strates within normal and transformed cells. Carfilzomib is a
tetrapeptide ketoepoxide-based proteasome inhibitor specific
for the chymotrypsin-like active site of the 20S proteasome.
Proteasome inhibition by carfilzomib interrupts cellular path-
ways integral to the survival of small cell lung cancer [2–4],
namely the dysregulated apoptotic pathway involving activated
nuclear factor-kB (NF-kB) [5]. NF-kB activates the transcrip-
tion of anti-apoptotic and proliferation genes, mediating tumor
cell survival in response to cytotoxic stress and resulting in
chemoresistance, a common problem in SCLC. Carfilzomib
prevents proteasomal degradation of IkB, the inhibitor of NF-
kB, and also modulates levels of the anti-apoptotic gene Bcl-2
and the tumor suppressor p53. Overexpression of Bcl-2, a key
mediator of resistance to apoptosis following chemotherapy, is
common in SCLC [4], and low levels of bcl-2 and b1-integrin
are associated with improved survival in SCLC [6].
Topoisomerase-1 is also overexpressed in SCLC [5] and is
thought to cause apoptosis via mechanisms other than NF-kB,
adding to the potential synergy of these compounds.
The results of in vitro and in vivo studies demonstrated the
importance of prolonged proteasome inhibition to anti-tumor
efficacy [7, 8] and the optimal dosing schedule of carfilzomib
as twice-weekly (Day 1 and 2) in a variety of hematologic and
solid tumor types. However, other schedules including once
weekly dosing are being explored in the clinic (NCT02335983).
Single-agent phase I studies of carfilzomib in solid tumors
revealed responses in SCLC, which led to the conception of
the present phase I, study in combination with irinotecan [9].
Irinotecan was chosen for its well-established activity in
SCLC as a single agent [10–12] and in combination with
platinum [13, 14]. Inactivation of proteasome function allows
for increased apoptosis and potential for enhanced antitumor
effects through enhanced apoptosis and non-cross reactive
mechanisms, and interference with Topo-I degradation.
Based on the hypothesis that carfilzomib would enhance
the anti-tumor efficacy of irinotecan in relapsed irinotecan-
sensitive cancers, we undertook the present phase I study
to determine the maximum tolerated dose (MTD) of this
combination.
Material and methods
The primary objective was to determine MTD of carfilzomib
(Day 1, 2, 8, 9, 15, and 16) in combination with irinotecan
(Days 1, 8 and 15) in subjects with relapsed irinotecan-
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sensitive cancers including small and non-small cell lung
cancer (NSCLC). Secondary objectives included response
rate (RR), safety/tolerability, and biomarker endpoints of
carfilzomib proteasome chymotrypsin-like activity in Is
this peripheral blood mononuclear cell (PBMC) (LMP7 and
b5 activity).
All subjects were informed of the investigational nature
of this study and signed Institutional Review Board (IRB)-
approved informed consent documents in accordance with
institutional and federal guidelines. Subjects were at least
18 years of age, with Zubrod performance status 0 or 1,
and histologically or cytologically-confirmed recurrent or
progressive irinotecan-sensitive cancer with no curative
therapeutic options. Subjects had measurable disease by
Response Evaluation Criteria In Solid Tumors (RECIST)
criteria [15], brain metastasis treated and asymptomatic if
present, no other therapy within: 14 days (chemotherapy),
21 days (radiation), or 28 days (surgery) prior to enroll-
ment and recovery from all associated toxicities of these
therapies. Subjects had normal bone marrow, renal and
hepatic function assessed within 14 days prior to enroll-
ment. Pregnant or nursing females were excluded and all
subjects agreed to use an effective contraceptive method.
Exclusion criteria included: prior use of irinotecan or
carfilzomib; leptomeningeal metastases; progression during
or within one month of completion of first-line platinum-
based chemotherapy; active infection, including human im-
munodeficiency virus (HIV) or hepatitis A, B or C; un-
stable angina or myocardial infarction within preceding
four months, New York Heart Association Class III or
IV heart failure, uncontrolled angina, significant conduc-
tion system abnormalities; uncontrolled hypertension or di-
abetes; evidence of moderate or severe pulmonary hyper-
tension; significant neuropathy (Grades [Gr] 3–4, or Gr 2
with pain); known allergy to Captisol®; other clinically
active cancer and or history of prior malignancy within
the past three years (exceptions: basal cell or squamous
skin cancer, thyroid cancer; carcinoma in situ of the cervix
or breast; prostate cancer of Gleason Gr 6 or less with
stable prostate-specific antigen levels; or other cancer con-
sidered cured by surgical resection).
Dose escalation is listed in Table 1. Per carfilzomib inves-
tigator brochure and safety instructions, Bstepped-up^ dosing
was required for all subjects on Cycle 1 Day 1 20 mg/m2,
with all subsequent doses as assigned by dose escalation
schema. Doses were calculated using the subject’s actual body
surface area (BSA), however, subjects with a BSA > 2.2 m2
received a capped dose based on a 2.2 m2 BSA. Dose adjust-
ments were made for greater than 10% change in body weight.
Dexamethasone premedication (8 mg) and intravenous (i.v.)
prehydration (250 to 500 mL of normal saline) was given prior
to all doses of carfilzomib during Cycle 1 and at investigator
discretion thereafter. Carfilzomib was supplied as a lyophilized
parenteral product in single-use vials and reconstituted with
sterile water for injection to a final carfilzomib concentra-
tion of 2.0 mg/mL. Commercially available irinotecan was
diluted with D5W or normal saline to a final concentration
of 0.12 to 2.8 mg/ml and administered via i.v. over 90 min
on dDays 1, 8, and 15. Carfilzomib was administered via
i.v. over 30 min on Days 1, 2, 8, 9, 15, and 16, after
irinotecan. Additional cycles of therapy could be adminis-
tered provided the subject had: absolute neutrophil count
(ANC) ≥ 1500/μL, platelets ≥100,000/μL, resolution of all
other Gr 2, 3 or 4 non-hematological toxicities and a creatinine
≤1.5 x IULN.
Subjects were evaluated for toxicity according to the
Common Terminology Criteria for Adverse Events (CTCAE)
version 4.0. A dose limiting toxicity (DLT) was defined as any
of the following treatment emergent toxicities with attribution
(possibly, probably or definitely related) to one or more of the
study drugs that occur during Cycle 1: ≥ Gr 2 neuropathy with
pain; any Gr 3 or 4 adverse event (excluding Gr 3 fatigue,
nausea, vomiting, diarrhea lasting <7 days); Gr 3 or 4 nausea,
vomiting, or diarrhea lasting >7 days despite maximal
antiemetic/antidiarrheal therapy; ≥ Gr 3 non-hematologic lab-
oratory findings if determined to be clinically significant, Gr 4
neutropenia lasting for ≥7 days; febrile neutropenia; Gr 4
thrombocytopenia lasting ≥7 days; Gr 3 or 4 thrombocytopenia
with bleeding; or any Gr 5 toxicity. Patients were
evaluable for DLT if they receive the assigned doses
and schedule of chemotherapy throughout Cycle 1 or
develop a DLT. If a patient did not develop a DLT,
but did not complete Cycle 1 for any reason, they were
considered not evaluable for DLT and replaced. Dose
reductions/adjustments were defined in the protocol
and no dose re-escalation was allowed. Criteria for removal
from protocol included: completion of six cycles of chemo-
therapy, progressive disease (PD), symptomatic deterioration
resulting in unacceptable toxicity, treatment delays greater
Table 1 Phase 1b dose escalation scheme
3 + 3 design Doses
Carfilzomib* Irinotecan
Cohort −2 20 mg/m2 75 mg/m2
Cohort −1 20 mg/m2 100 mg/m2
Cohort 1 20/27 mg/m2 125 mg/m2
Cohort 2 20/36 mg/m2 125 mg/m2
Cohort 3 20/45 mg/m2 125 mg/m2
Cohort 4 20/56 mg/m2 125 mg/m2
Cohort 5 20/70 mg/m2 125 mg/m2
Cycle 1 Day 1 and Day 2 doses are 20 mg/m2. All subsequent days as
specified, i.e. 20/27 mg/m2 means Cycle 1 Day 1 and Day 2 doses are
20 mg/m2 and all other days are 27 mg/m2
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than three weeks, or removal at the discretion of the treating
physician or withdrawal by patient.
Serial blood samples were collected on Day 1 pre-
irinotecan, and at ~90 min, ~2 h, ~5.5 h (relative to
the start of irinotecan), and Day 2: pre-carfilzomib in-
fusion. The dose dependent proteasome inhibition was
determined in purified PBMCbymeasuring the chymotrypsin-
like activity.
The primary endpoint for this phase I trial was deter-
mination of the MTD. The decision rules followed the
modified Fibonnaci design (3 + 3). With this design, at
least six patients are evaluated at the dose level chosen as
the MTD. Assuming that a Cycle 1 DLT rate of 25% is
acceptable, if the true rate of Cycle 1 DLT were 40%, and a
dose level is rejected with two or more out of six experiencing
DLT, this design has 77% power to reject the null hypothesis
of an acceptable DLT rate.
The secondary endpoints of progression-free survival
(PFS), response to treatment, and rates of adverse events were
calculated based on all eligible subjects who received at least
the first day of treatment. Survival was estimated using the
Kaplan-Meier method. Responses were evaluated by RECIST
version 1.1 approximately every six weeks. Objective
responses were confirmed at least four weeks later.
PFS is defined as the date of registration to the date
of first documentation of progression by RECIST 1.1
criteria, or death due to any cause. Subjects last known
to be alive and progression free are censored at the date
of last contact. Due to the limited samples size in this
study, analyses of secondary endpoints and correlative
studies were considered to be exploratory in nature.
Results
Patient characteristics and treatment delivery
From October 30, 2013 to January 20, 2015, 22 patients were
screened and 16 patients were enrolled and treated on this
phase Ib trial after providing informed consent. Four patients
had to be replaced because of Cycle 1 treatment could not be
completed and a DLTwas not observed. Baseline characteris-
tics are listed in Table 2. The majority of enrolled subjects had
lung cancer (twoNSCLC, 13 SCLC). One subject had ovarian
cancer. Fifteen patients (93%) were Caucasian, 50% were
male.
Overall, 16 patients received at least one day of chemother-
apy. One subject completed all cycles of therapy, 12 subjects
discontinued treatment prior to six cycles due to disease pro-
gression, two subjects refused further treatment for reasons
other than adverse events, and one subject withdrew because
adverse events related to treatment were intolerable to the
patient. This patient refused to continue at a lower irinotecan
dose. Overall, one subject completed four and one completed
six cycles of therapy, two subjects completed two and three
cycles of therapy, respectively, six completed one cycle of
therapy and four subjects did not complete the first cycle of
therapy.
One patient on Cohort 3 had a dose delay at Cycle 2 Day 1
due to thrombocytopenia (a DLT from Cycle 1). This patient
was able to continue with treatment after delay and completed
three cycles. A patient in Cohort 2 had the Cycle 2 dose
reduced for both drugs due to Gr 1 (GI) gastrointestinal
toxicities and fatigue, and continued on to complete four
Table 2 Patient characteristics for 16 eligible patients
Patient Characteristics Cohort 1: 20/27 mg/m2
Carfilzomib, 125 mg/m2
Irinotecan
Cohort 2: 20/36 mg/m2
Carfilzomib, 125 mg/m2
Irinotecan
Cohort 3: 20/45 mg/m2
Carfilzomib, 125 mg/m2
Irinotecan
Overall
Sex
Female 3 (75%) 4 (44%) 1 (33%) 8 (50%)
Male 1 (25%) 5 (55%) 2 (66%) 8 (50%)
Performance Status
0 0 0 3 (33%) 0 0 3 (18%)
1 4 (100%) 6 (66%) 3 (100%) 13 (81%)
Histology
Adenocarcinoma (Lung) 1 (25%) 0 0 0 0 1 (6%)
Ovarian 0 0 1 (11%) 0 0 1 (6%)
SCLC 3 (75%) 7 (77%) 3 (100%) 13 (81%)
Mixed SC/NSCLC 0 0 1 (11%) 0 0 1 (6%)
Race
Black 1 (25%) 0 0 0 0 1 (6%)
White 3 (75%) 9 (100%) 3 (100%) 15 (93%)
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Table 3 Adverse events over all treatment cohorts. Events possibly, likely, or definitely related to treatment are included
Maximum Grade AEs with attribution Possible Probable or Definite
All Eligible Patients (N = 16)
Adverse Event Description 1 2 3 4 5
Blood and lymphatic system disorders 1 (6%) 1 (6%)
Anemia 1 (6%) 1 (6%)
Cardiac disorders 1 (6%)
Cardiac disorder-Other, specify 1 (6%)
Gastrointestinal disorders 4 (25%) 5 (31%) 3 (19%)
Abdominal pain 1 (6%)
Constipation 1 (6%)
Diarrhea 2 (13%) 4 (25%) 2 (13%)
Nausea 4 (25%) 2 (13%) 1 (6%)
Vomiting 2 (13%) 1 (6%)
GI disorders-Other, specify 2 (13%)
General disorders and administration site conditions 2 (13%) 3 (19%) 3 (19%)
Edema limbs 1 (6%)
Fatigue 3 (19%) 2 (13%) 3 (19%)
Infusion related reaction 1 (6%)
Infections and infestations 2 (13%)
Urinary tract infection 2 (13%)
Vaginal infection 1 (6%)
Injury, poisoning and procedural complications 1 (6%)
Fall 1 (6%)
Investigations 1 (6%) 2 (13%) 2 (13%) 2 (13%)
ALT increased 1 (6%)
AST increased 1 (6%)
Alkaline phosphatase increased 1 (6%)
Creatinine increased 1 (6%)
Lymphocyte count decreased 1 (6%)
Neutrophil count decreased 1 (6%) 1 (6%) 1 (6%)
Platelet count decreased 1 (6%) 3 (19%)
Weight loss 1 (6%)
White blood cell decreased 2 (13%) 1 (6%)
Investigations-Other, specify 1 (6%)
Metabolism and nutrition disorders 1 (6%) 2 (13%) 3 (19%)
Anorexia 1 (6%) 1 (6%)
Dehydration 1 (6%) 1 (6%) 1 (6%)
Hypoalbuminemia 1 (6%)
Hypocalcemia 1 (6%)
Hypokalemia 1 (6%)
Hypomagnesemia 1 (6%)
Hyponatremia 1 (6%) 1 (6%)
Musculoskeletal and connective tissue disorders 1 (6%)
Generalized muscle weakness 1 (6%)
Nervous system disorders 3 (19%)
Dizziness 1 (6%)
Peripheral sensory neuropathy 1 (6%)
Tremor 1 (6%)
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cycles. Another patient in Cohort 2 was required to hold Days
8 and 9 for creatinine clearance, successfully restarting on day
15. A patient on Cohort 3 was held for Cycle 1 Days 15 and 16
due to diarrhea (a DLT) and subsequently restarted with Cycle
2 after a delay and a reduction to dose level 2. This patient
received four cycles of treatment.
Safety
Three patients experienced DLTs with one in Cohort 2
(dehydration), and two in Cohort 3 (dehydration and diarrhea),
exceeding the MTD in Cohort 3. With only one DLT in six
patients in Cohort 2, theMTDwas 20/36mg/m2 of carfilzomib
(given on Days 1, 2, 8, 9, 15, and 16) and 125 mg/m2 of
irinotecan (Days 1, 8 and 15). The course of the study, one
patient on Cohort 1 and three patients on Cohort 2 were not
evaluable for DLT because they did not finish Cycle 1. All
toxicities (with attribution ruled as possibly, likely, or definitely
related to treatment) are listed in Table 3. Common Gr 3 and 4
toxicities included: fatigue (19%), thrombocytopenia (19%),
and diarrhea (13%). At Gr 3, there was one report each of:
hyponatremia, muscle weakness, hypocalcemia, dehydration,
anemia, nausea, and vomiting. At Gr 4, there was one report
each (6% of patients) of: decreased neutrophils, decreased
lymphocytes, and decreased white blood cells.
Pharmacodynamics
Carfilzomib specifically functions as an inhibitor of the
chymotrypsin-like activity of the 20S proteasome, which
Table 3 (continued)
Maximum Grade AEs with attribution Possible Probable or Definite
All Eligible Patients (N = 16)
Adverse Event Description 1 2 3 4 5
Psychiatric disorders 2 (13%)
Confusion 1 (6%)
Insomnia 1 (6%)
Renal and urinary disorders 1 (6%) 1 (6%)
Urinary retention 1 (6%)
Renal/urinary disorders-Other 1 (6%)
Respiratory, thoracic and mediastinal disorders 1 (6%)
Atelectasis 1 (6%)
Productive cough 1 (6%)
Skin and subcutaneous tissue disorders 2 (13%)
Alopecia 1 (6%)
Rash maculo-papular 1 (6%)
Skin/subq tissue ds-Other 1 (6%)
Vascular disorders 1 (6%) 1 (6%)
Hot flashes 1 (6%)
Hypotension 1 (6%)
Maximum Grade Any Toxicity 3 (19%) 4 (25%) 6 (38%) 2 (13%) 0
Fig. 1 Time dependent change, relative to pretreatment, of the chemotrypsin-like activity (CLA) in isolated PBMC from patients receiving 20/27, 20/36, and
2045 mg/m2 carfilzomib. Data are represented as the geometric mean and 95%CI of the ratio of CLA relative to the pretreatment value
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leads to the accumulation of protein substrates within the cell
and induction of apoptosis. We analyzed chymotrypsin-like
activity in PBMCs in order to monitor the pharmacologic
target of carfilzomib and to evaluate its correlation with effi-
cacy in a preliminary fashion. Analysis of lysates from isolat-
ed PBMCs was conducted in 16 patients. Overall, there was a
time dependent decrease in the chymotrypsin-like activity
(CLA) of the proteasome. Figure 1 depicts the changes in
CLA relative to pretreatment in the three dosing cohorts.
Values are presented as the geometric mean and 95% CI.
Decreased CLA activity was noted within two hours.
Efficacy
There were three partial responses (PR), one per dose level, with
one confirmed, for a overall (ORR) of 19%. One patient had
stable disease (6%) for a disease control rate (DCR) of 25%. The
confirmed PR occurred in a Cohort 1 patient (SCLC) who com-
pleted six cycles of treatment, and the response was sustained
for four months following cessation of therapy. The two uncon-
firmed PRs occurred in a Cohort 2 patient who received four
cycles and a Cohort 3 patient who received three cycles.
Another Cohort 3 patient had stable disease after three treatment
cycles. All cases of response and stable disease occurred in
patients with SCLC. Two patients who withdrew voluntarily
from treatment were not assessable for response. The remaining
12 patients had progressive disease. Two patients remained alive
and progression free at analysis time. The median PFS estimate
was 1.6 months (95% CI: 1.2–3.6 months). The estimated six
month PFS rate was 7% (95% CI: 0%–20%).
Discussion
The combination of irinotecan and carfilzomib was safe and
tolerable with the MTD of 20/45 mg/m2 of carfilzomib and
125 mg/m2 of irinotecan in this patient population of
irinotecan-sensitive solid tumors. Stepped-up dosing was in-
corporated into this trial based on observations of acute tumor
lysis syndrome (TLS) in previous studies of carfilzomib in
hematologic patients. However, no evidence of TLS was seen
in the patients treated on this study. Premedication with dexa-
methasone led to a much lower rate of infusion reactions than
reported in earlier studies; only one patient had a Gr 2 infusion
reaction, which responded to medical management and did
not recur after reinstitution of dexamethasone premedication.
DLTs included fatigue, thrombocytopenia, and neutropenic
fever. Other toxicities weremanageable and included diarrhea,
decreased white blood cells and neutrophils, and others listed
in Table 3. Two subjects discontinued therapy because of poor
tolerance, indicating that dose reduction and earlymanagement
of diarrhea, dehydration, and low blood counts is important
with this regimen to allow subjects to tolerate it.
Antitumor activity was noted in one subject with a PR after
six cycles that was sustained for three additional months
(SCLC) and two subjects with stable disease for greater than
two cycles (SCLC and NSCLC). In this heavily pre-treated
group of patients, the RR of 18% and DCR of 24% are
encouraging, especially coupled one sustained PR for four
months following completion of six cycles of therapy. The
combination of carfilzomib and irinotecan is currently being
evaluated in SCLC in the phase II portion of this study
(NCT01941316).
Combination treatment using carfilzomib with irinotecan
was anticipated to: a) enhance anti-tumor effect via inactiva-
tion of proteasome function and increased apoptosis; b)
synergize with irinotecan via the different mechanisms of ap-
optosis of the compounds; and c) interfere with topo-I degra-
dation, resulting in enhanced anti-tumor effect. Correlative
studies confirmed decrease in chymotrypsin-like activity in
the majority of patients, indicating proteasome inhibition
was potent, ongoing, and not adversely affected by irinotecan.
In summary, the combination of irinotecan and carfilzomib
was well tolerated in this heavily pretreated cohort of subjects
with relapsed solid tumors. The most common toxicities were
fatigue, thrombocytopenia and neutropenic fever. Objective
clinical response was seen in one patient with SCLC. A dose
of carfilzomib 20/36 mg/m2 and irinotecan125 mg/m2 was
selected for further evaluation in the ongoing phase II study
of this combination in SCLC. This phase II evaluation will
help further characterize the efficacy of this combination in
relapsed SCLC.
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